Dr Reddy’s Laboratories has moved higher by 1% to Rs 2,315 after the company said it has launched Decitabine for injection, a therapeutic equivalent generic version of Dacogen in the US market on July 11, 2013.
The company has launched Decitabine for injection following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Decitabine for Injection, Dr Reddy’s Lab said in a press release.
The Dacogen brand has US sales of approximately $260 Million MAT for the most recent twelve months ending in July 2013 according to IMS Health. Dr Reddy’s Decitabine for injection 50 mg is available as a single dose vial, it added.
Meanwhile, the foreign institutional investors (FIIs) have increased their holdings in Dr Reddy’s Laboratories by over 3 percentage points to 32.69% during June 2013 quarter. FIIs held 29.66% stake at the end of March 2013 quarter.
The stock opened at Rs 2,301 and hit a record high of Rs 2,317 on NSE. A combined 158,729 shares have changed hands on the counter so far on NSE and BSE.
The company has launched Decitabine for injection following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Decitabine for Injection, Dr Reddy’s Lab said in a press release.
The Dacogen brand has US sales of approximately $260 Million MAT for the most recent twelve months ending in July 2013 according to IMS Health. Dr Reddy’s Decitabine for injection 50 mg is available as a single dose vial, it added.
Meanwhile, the foreign institutional investors (FIIs) have increased their holdings in Dr Reddy’s Laboratories by over 3 percentage points to 32.69% during June 2013 quarter. FIIs held 29.66% stake at the end of March 2013 quarter.
The stock opened at Rs 2,301 and hit a record high of Rs 2,317 on NSE. A combined 158,729 shares have changed hands on the counter so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%